Immunotech Biopharm Ltd
Company Profile
Business description
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
Contact
No.1 Kangding Street
8th Floor, Block 1, Guosheng Technology Park
Beijing Economic-technological Development Area
Beijing100176
CHNT: +86 8610884002
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
189
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
stocks
Investors too optimistic about overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,956.60 | 12.40 | 0.14% |
| CAC 40 | 7,921.68 | 83.19 | 1.06% |
| DAX 40 | 25,645.04 | 340.62 | 1.35% |
| Dow JONES (US) | 52,856.09 | 360.21 | 0.69% |
| FTSE 100 | 10,752.88 | 19.88 | 0.19% |
| HKSE | 23,651.87 | 215.87 | -0.90% |
| NASDAQ | 26,702.86 | 278.04 | 1.05% |
| Nikkei 225 | 64,621.24 | 545.82 | 0.85% |
| NZX 50 Index | 13,832.36 | 71.07 | 0.52% |
| S&P 500 | 7,757.17 | 44.60 | 0.58% |
| S&P/ASX 200 | 8,831.30 | 14.40 | 0.16% |
| SSE Composite Index | 3,713.03 | 22.34 | -0.60% |